Greetings, and welcome to the Field Trip fiscal fourth quarter and full year 2022 earnings conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the call over to Kathleen Heaney of Investor Relations. Thank you. You may begin. Good morning, and welcome to Field Trip's fourth quarter and earnings conference call. Before we begin the call, I am obligated to remind everyone that during the course of this conference call, management may be making some forward-looking statements that are based on current expectations and are subject to a number of risks and uncertainties that may cause actual results to differ materially from expectations. These results are outlined in the Risk Factors section of the company's filings and disclosure materials. Any forward-looking statements should be considered in light of these factors. Please also note that safe harbor, any outlook we present is as of today, and management does not undertake any obligations to revise any forward-looking statements in the future. Presenting today will be Joseph del Moral, Co-founder and Chief Executive Officer, Ronan Levy, Co-founder and Executive Chairman, and Donna Wong, Chief Financial Officer. I'll now turn the call over to Joseph to begin today's presentation with an update on the spin-out transaction. Thank you, Kathleen, and welcome to everyone joining us this morning. As previously disclosed, the strategic review confirmed that both divisions of Field Trip are equipped and ready to successfully operate as independent companies with distinct strategies, dedicated management teams, and the capital resources required to execute on the respective business priorities. We are pleased to say that we are nearing the finish line. This past Monday, shareholders approved the arrangement and concurrent financing, thereby approving the spin-out transaction. Subject to completion of the arrangement, shareholders also approved the Field Trip Health & Wellness equity incentive plan and authorized Field Trip Health & Wellness to reserve and allot for issuance and issue upon the exercise of options up to 10% of the number of common shares in Field Trip Health & Wellness issued and outstanding from time to time on a non-diluted basis. Just yesterday, we received the final court approval for the spin-out transaction. The closing of the arrangement remains subject to regulatory approvals, including conditional listing approval by the TSX Venture Exchange. It is expected that the closing of the arrangement will occur on or around August 2022. At that time, the individual companies will be named Reunion Neuroscience Inc. for drug discovery business, which will continue to focus on the research and development of novel psychedelic molecules such as FT-104, and Field Trip Health & Wellness, which will house the clinics and technology business and will continue its focus on developing proprietary, competitive, and differentiated psychedelic-assisted therapies through innovation in therapeutic protocols. On closing, it is expected that each share of the company will be exchanged for one common share of Reunion and approximately 0.86 common shares of Field Trip Health & Wellness. Additionally, Reunion will remain listed on the Nasdaq Stock Market and Toronto Stock Exchange, and Field Trip Health & Wellness, subject to exchange approval, will list on the TSX Venture Exchange. We were pleased to secure the financing to execute on our plan given the current challenging market environment. Concurrent with closing of the spin-out transaction, Field Trip Health & Wellness is expected to complete a series of private placement financings for gross proceeds of CAD 20 million, led by Oasis Management Company and Field Trip. This is expected to be sufficient to support the growth of the business as well as enable the company to reach breakeven. Now that the spin-off has been approved by the shareholders and as we undertake the separation, it is key that we preserve the synergies that currently exist as well as the wealth of knowledge that we've accumulated over the past two years. We are now focused on the future for the separate drug development and clinics businesses and allowing them to execute on their respective strategic priorities. I will now hand the call over to Ronan to provide an update on Field Trip Health & Wellness. Thanks, Joseph, and welcome everyone. Throughout the fourth quarter, the clinics achieved operational efficiencies, increased customer reach and patient throughput, along with launching innovative strategic partnerships to offer new psychedelic-assisted treatment options. In turn, we were pleased to see ongoing sequential growth in patient revenues in the quarter, which were up 27% to CAD 1.72 million. On a year-over-year basis, revenue was more than three times higher than the same period of the prior year. During the quarter, we opened two clinics, one in Vancouver, British Columbia, and the other one in Washington, D.C. Coming out of the strategic review and with the increased emphasis on client acquisition through digital platforms as well as ongoing efficiency improvements, we made the decision to defer the opening of new clinics, which currently stands at 12 in total. Subsequent to quarter end, we launched Field Trip at Home powered by Nue Life, which provides ketamine treatments from the comfort of a person's home, which is an alternative to in-clinic care. With this relationship, we now offer increased accessibility and convenience for those interested in pursuing the successful treatment outcomes of ketamine therapy outside of a clinic setting through Nue Life's at-home and telehealth offerings. We are proud that our Field Trip Health centers have played a pivotal role in providing access to ketamine and psilocybin-assisted treatments and have helped change the lives of those living with depression, anxiety, and other mental health conditions. Over the coming months, you will start to see an evolution in the business strategy for the clinics division as it becomes Field Trip Health & Wellness. The focus to date has been on validating that psychedelic-assisted therapies can be safely, effectively, and viably offered as a therapeutic option for the millions of people who struggle with mental health challenges. Of course, we will continue to build upon our strong foundation as a leader in the industry with a focus on growth in client numbers while also implementing further operational improvements to scale our physical footprint efficiently. However, now there will be new emphasis on expanding the Field Trip ecosystem in a capital efficient manner. This will include building on the successful launch of our Field Trip at Home program and a greater emphasis on our digital tools, particularly our Trip app, which will start to play a much more central role as the conversation around psychedelics emerges from a third line treatment in treating DSM-5 diagnoses to a much more social and cultural conversation. The opportunities in the psychedelic industry as it continues to evolve are near boundless. With Field Trip Health & Wellness, we plan to be at the forefront of the most exciting ones. I'll now turn the call back to Joseph to provide an update on the drug development side of the business. Thanks, Ronan. During the fiscal fourth quarter and full year 2022, we continued to advance our important drug discovery work. We are leading the development of the next generation of custom synthetic molecules targeting serotonin 5-HT2A receptors with FT-104, our first drug candidate in development. FT-104, given the name Isoprocin Glutarate, is anticipated to produce a psychedelic trip of about two-three hours, significantly shorter than other molecules currently in clinical trials. The structure of FT-104 is based on classical serotonin 2A psychedelics like psilocybin, which have been reported to be useful in treating a variety of mood disorders, including depression, anxiety, and substance abuse. We completed phase I enabling studies for FT-104 earlier in the year and have entered clinical stage development. During the fourth quarter, we entered into an agreement with an Australian clinical research organization to perform a phase I trial with the objective of studying the safety, tolerability, and pharmacokinetics of single escalating doses of FT-104 in healthy human volunteer participants. Additionally, exploratory objectives include characterization of the intensity, duration, and subjective feeling of the psychoactive experience produced by the study drug. The phase I protocol was developed in collaboration with our CRO and our clinical advisory team, was approved by the Human Research Ethics Committee, and is being implemented at the clinical trial site where screening and recruitment have begun. Dosing of participants in the study is expected to begin shortly. An important event subsequent to quarter end was the granting of the patent for claims related to FT-104, with protection to at least mid-2040. The patent application grants exclusive rights to Field Trip for the composition of matter formulations, methods of use, and methods of manufacture for a family of hemiester compounds of hydroxytryptamine, including isoprocin. During the quarter, we also progressed with our FT-200 molecule group. To date, our research has revealed that candidates in the FT-200 group are demonstrating interesting pharmacological differences with classical psychedelics. This may potentially make them safer serotonin 2A agonists with a broader use potential in mental health care. Furthermore, by decreasing the relative activity of the serotonin 2B receptor, we are aiming to improve their cardiovascular safety profile. Molecules with the ability to selectively activate the 5-HT2A receptor, but not the 5-HT2B receptor, could potentially be used as medications for depression or anxiety, but in a manner more closely resembling traditional pharmaceuticals with, for example, at-home daily dosing. I will now turn the call over to Donna to discuss our financial results. Thank you, Joseph, and good morning everyone. As a reminder, all figures that I will be discussing are in Canadian dollars, and the fourth fiscal quarter and fiscal year 2022 corresponds to the three and 12-month periods ended March 31st, 2022. During the fourth quarter, we earned patient services revenues of CAD 1.7 million from our 12 clinics, an increase of 228% over the comparative quarter in the prior year. The Washington, D.C. clinic began generating revenues in March of this year. By contrast, fourth quarter 2021 patient services revenues were generated from five clinics and amounted to CAD 526,000. We are pleased with the 26.7% sequential increase in revenues. This was due in part to the one additional clinic as compared to the prior quarter, as well as the steps the company has taken to further improve and increase throughput, as Ronan mentioned. For the fiscal year, revenue was CAD 4.7 million, an increase of 406% over fiscal 2021. This reflects the increase in the number of clinics we had, 12 in the most recent year compared to three in the prior year. Moving now to a discussion of cost. Our efforts to streamline operating costs are well underway, and we are beginning to see evidence of that improvement on a sequential basis as fourth quarter total operating expenses were 8.3% lower than the third quarter, while at the same time we grew revenue 27%. On a year-over-year basis, total operating costs in the fourth quarter were CAD 14.3 million, up from CAD 7.7 million in the same comparative period, and reflects our investments in growing and scaling both our clinics and drug development businesses. The amount expended for fiscal year 2022 was CAD 58 million, compared with CAD 20 million in the comparative year, with the increase reflecting the items I just mentioned, as well as an increase in sales and marketing and R&D costs. General and administrative expenses of CAD 7.4 million are our largest operating expenses and were up from CAD 4.1 million in the same quarter of the prior year. The increase was primarily due to operating costs, reflecting the much larger number of clinics operating in the quarter as compared to the prior year, and an increase in public company related expenses. G&A costs in the quarter also included non-cash items comprised of share-based payments of CAD 1.3 million, D&A of CAD 1.1 million, and one-time costs associated with the spin-out transaction of approximately CAD 900,000. Total G&A for the fiscal 2022 year end was CAD 32.3 million, up from CAD 10.5 million in fiscal 2021 for the reasons I just mentioned. Patient services expenses of CAD 2.7 million and CAD 9.2 million for the fourth quarter and full year respectively compares with CAD 1 million and CAD 2 million for the comparable periods in fiscal 2021. The increase reflects the larger number of clinics in operation. Our fourth quarter R&D costs were CAD 2.3 million, an increase of 153% over the prior year, primarily due to ramping up of development costs as we work to further progress the development of the active ingredient FT-104, as you just heard from Joseph. R&D costs of CAD 7.3 million for the full year reflect the continued investment as we enter the clinical stage of development and prepare for phase II. In line with the actions we have taken to improve efficiencies, marketing costs of CAD 400,000 in fourth quarter 2022 were 39% lower in the same period of the prior year, primarily reflecting lower branding and public relations fees. On a full year basis, sales and marketing expenses of CAD 3.9 million reflect increased paid social search and public relations expenditures to build patient interest and our brand. This had the desired results as we saw steady growth in client acquisitions and patient services throughout the year. Now turning next to the balance sheet. Field Trip at year-end had unrestricted cash and cash equivalents of CAD 64 million. Following our CAD 9.8 million capital infusion into the standalone clinics business on a pro forma basis upon closing, the cash position for Reunion, our new name at that time, is estimated at CAD 42 million to support our ongoing drug discovery work. This ends our prepared remarks. I'll now ask the operator to open the lines for the Q&A session. Thank you. We will now be conducting a question-and-answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment please, while we poll for your questions. Our first question has come from the line of Andrew Partheniou with Stifel. Please proceed with your questions. Hi, good morning. Thank you for taking my questions. Hi, Andrew. Good morning. The first thing I'd just like to touch on, and I'm not sure if I heard correctly, Donna, my phone cut off there. I think you mentioned CAD 42 million in pro forma cash for Reunion post the spin-out transaction. Oh, yep. Sorry, Andrew. CAD 40.2 million. CAD 40.2 million. Okay. Yes. Could you talk a little bit about how long or what do you think that cash will enable you to achieve in Reunion? In other words, you know, what do you expect your cash burn to be in Reunion? On the other side of the coin, for Field Trip Health & Wellness, you know, where do you expect your pro forma cash position to be post the spin out? Again, you know, what do you think the cash burn will be in Health and Wellness and where do you think or what do you think that cash will enable you to achieve? Okay. Thanks, Andrew. Joseph. I can maybe answer both about Reunion or we expect to be able to achieve with the cash and Donna jump in with any additional commentary. The cash we will have at Reunion when we effect the separation will get us through our phase I trial, which we expect to have data by the end of this year and set us up in that position. Sorry. Also do all the preparatory work to get ready to run our phase II trials next year. Do our pre-IND and meetings and get everything lined up for our phase II. It also set us up to have the cash runway we need to do a fundraise prior to starting our phase II to fund the phase II trials. We'll have more detail about exactly how much runway that is and timelines and milestones as we get further along. I think it sets us up well to get all the data we need from our phase I and prepare everything we need to launch the phase II and then do a successful fundraise for our phase II trial before starting the phase II. Okay. On the Field Trip Health & Wellness side, upon the close of transaction, the clinics business will have CAD 20 million in gross proceeds to fund the operations on an ongoing basis. The company believes, based on our current fiscal forecast, our current revenue forecast, that the funding should be sufficient to take us through to profitability. Thank you very much for that. Could you talk a little bit about the Reunion phase I that's has already started, I believe you mentioned recruitment is ongoing and dosing should start shortly. Could you talk a little bit about, you know, how is recruitment going? What are you seeing thus far? Is there a lot of interest in participating in a trial like this? Any kind of color like that would be useful. Sure. I'll hand that question over to Nathan. Good morning, Andrew. Yes, we started advertising only a couple of weeks ago, and we've had hundreds of inquiries. Right now what we're doing is running through those and selecting out the eligible candidates and getting them into screening as fast as possible so that we can get them scheduled for dosing. It does seem quite that there's an avid appetite for participating in this study. That's great. Just on the clinic side, last question for me. You know, is there any kind of color that you can provide on where you are in terms of profitability? You know, namely, you know, your oldest clinics, which are typically the ones that perform the best. You know, how do you think that the Nue Life partnership will play a role in helping you achieve that profitability milestone? Thanks, Andrew. We'll hand that over to Ronan to answer. Yeah. Thanks, Andrew. I mean, you're spot on when it comes to the growth of the clinics. The oldest clinics are certainly achieving capacity faster than the younger clinics, and they all seem to follow the same general trajectory of growth. We haven't specifically outlined individual by clinic profits or anything along those lines, so I have to be a little bit conscientious about what we say. The trend lines kind of continue in the same direction. In some case, I think the growth in the established clinics may actually be accelerating. That's positive. In terms of the Nue Life partnership, you know, it's only been about six weeks since it's launched. It's hard to parse out exact details other than to say we are seeing very positive early signs of it in terms of the conversions of patients that go through us and ultimately land into the Field Trip at Home powered by Nue Life offering. We think it's an excellent opportunity because there's virtually zero capital outlay and it's a way to monetize the awareness that we generate to people who aren't in the geographic jurisdictions of our clinics. Initial signs are very positive and encouraging, but it's still very early days so we can't offer too much insight past that right now. Thank you very much for that, and I'll get back in the queue. Thanks, Andrew. Thank you. Our next question comes from the line of Patrick Trucchio with H.C. Wainwright. Please proceed with your questions. Thanks. Hi. Good morning, and congrats on all the progress. I have a few follow-up questions on FT-104. I guess just first, regarding the clinical path forward, can you tell us what you're looking to see in this phase I data from a PK and safety perspective, though also from the psychedelic experience perspective that would give you confidence to move ahead to the phase II and PPD? Good morning, Andrew. I mean, sorry, Patrick. Yes. What we're looking for, primarily, and of course we expect to see safety. We wanna see that, you know, there's no adverse events that are gonna cause us from being able to use the doses that are psychedelic in nature. We'll be using, you know, standard questionnaires to get a measure of drug intensity and subjective experience to help us guide us in what produces the maximum experience without any safety concerns as those will be the doses that we'll be selecting most likely for use in our phase II program. That's really the ultimate goal is to understand where our limits are, our upper limit of tolerability is, and dose below that that gives the highest psychedelic experience but no untoward adverse event. That's the key point that we'll be looking for. Of course, we always wanna make sure the safety is primary for our patients, so that's the biggest thing. Got it. For those- As for the duration. Yeah, sorry. I was gonna say I didn't mention the duration, but of course the duration is a key component to what we want to be able to demonstrate. It's the key component of what we were after in the first place, is to demonstrate that, as has been said by people who've used this in the illicit space, that the psychedelic experience is typically three hours or less. Yeah. That's helpful. If all does go as well as expected, when would you anticipate the phase II and PPD to be up and running? Can you give us some expectations around this program, including, you know, the potential differentiation from brexanolone, but also differentiation from other psychedelic programs that could emerge, you know, such as 5-MeO-DMT? Starting the phase II will obviously be gated by the financing. Successful early financing, I think that our earliest start date would be Q3 2023. As for the design, I think I'll wait until we've had some feedback from the FDA before we talk about that. In comparison, most of the comparisons right now to the products such as brexanolone would be theoretical of course, you know, what we're trying to demonstrate is that in PPD, which is what we're gonna study this drug in, that we could treat a mother, have symptom relief within 24 hours, which is typical of most psychedelics, and have a return to breastfeeding within that same time frame, which differentiates from brexanolone, which right now is a 60-hour infusion, and for which mothers are told to withhold breast milk for at least a week after those three days of continuous infusion. I think there's a big jump in convenience for mothers to have only a half day in a clinic and be able to return to normal life, if you wish, rather than three days away in a hospital, you know, where they're obviously seen as patients and not just as being treated quickly in a care facility that would only need them for a half day. Those are the major concerns. As for other psychedelics, 5-MeO-DMT, if you're talking about GH Research and their foray potentially into PPD, I'm not gonna comment right now on that. I have, you know, not much information to compare to yet. Got it. If I could, just one on the clinics and the separation. You know, Reunion is expected to maintain equity ownership of 21.79% in Field Trip Health & Wellness. I'm wondering if Reunion will have input into managerial decisions, and if it would have earlier special access to data outcomes from psychedelic-assisted therapies administered at the clinics. As we mentioned before, we will be entering into a collaboration agreement between the two companies that will maintain some of the synergies we have currently from having both of these divisions under one roof. That would include access to anonymized sort of outcome information, data, access for preferential access to clinical trial sites and that sort of thing. In terms of managerial influence over managerial decisions, that's not expected, although we may have the rights to appoint a director to the board. That would be sort of the path we'd choose to go on that front. Maybe I'll hand it over to Paula for any other comments. Otherwise, we'll move on. Hey, Joseph. Thank you very much. You're entirely correct. Our plan is to have two agreements in place. One is, shared services, which will allow the two companies to leverage shared back office staff for a period of time, but it's not intended to be managerial in nature. It's meant to be more fiscal and to smooth the transition. Joseph has also correctly described the ongoing collaboration agreement that we intend to enter into prior to closing. Thank you very much. That's helpful. Thank you so much. Thanks, Patrick. Thank you. Our next question has come from the line of Elemer Piros with ROTH Capital Partners. Please proceed with your questions. Hello? Elemer. We can hear you now, Elemer. Yes. Sorry about that. I was fiddling with the phone. I just have a couple of leftover miscellaneous questions. Joseph, what do you envision that the headcount is going to be at Reunion, when you get, when separate from Field Trip? We have about 10 people who are working on the clinical development CMC side, and then a few people on sort of general corporate support, finance, and legal, et cetera. It's not a huge team. We obviously do leverage virtual. A lot of our work is done virtually with CROs and consultants. Okay. Thank you. Previously you mentioned that the phase I trial with FT-104 will be also conducted at the Netherlands. Is it Australia only now? That's correct. We made the move to Australia, so the phase I is Australia only. Okay. Besides the phase I results, what else you might need to generate sort of preclinical data for an IND filing? I'll hand that over to Nathan. Hi, Elemer. We actually believe we have just about everything we need for an IND filing. Else we wouldn't have been able to start the phase I study in Australia. They also require a fairly hefty investigator's brochure with complete, you know, preclinical tox data. However, we have worked with consultants to look at a gap analysis. We have identified a couple of things that we feel that the FDA may request in addition to what we have. Those have been started. Then, hopefully we're gonna go to the FDA in September. We'll share with them what we've done and what is in progress, and Seek their guidance as to whether anything else is additionally necessary prior to starting the phase II. We'll try to get it done before that July 2023 date, if at all possible. Of course, it would have to be done before the phase II, unless we can argue otherwise. That's the plan right now. Try to get the FDA's guidance, based on what we have and what's ongoing, and then complete anything necessary before July 2023. Thank you very much, Nathan, and congratulations on the approval of the separation. Thank you, Elemer. Thank you. Thank you. As a reminder, if you would like to ask a question, please press star one on your telephone keypad. Our next question comes from the line of Michael Okunewitch with Maxim Group. Please proceed with your questions. Hey, guys. Good morning. Thank you for taking the questions. Good morning. I guess to direct my first one to Ronan. If you could talk a bit more about the logistics of the at-home program. Regulatory-wise, how does that work given that ketamine is a scheduled substance and it's an off-label treatment, and how does at home impact your treatment capacity? Sure. I'd invite Paula to offer any additional comments that I don't touch on. From a regulatory perspective, there's nothing particularly unique about the at-home offering. Physicians and other qualified prescribers are able to prescribe ketamine, provided they have a DEA license. As far as I know, there's never been a requirement to have it administered in clinic. The at-home program, you know, is just working within the normal confines of prescribing ketamine and the delivery and/or administration of ketamine. There's nothing particularly unique about that. The way it's set up from our perspective in terms of the patient relationships between us and Nue Life. Essentially, Nue Life is the provider of care. All kind of regulatory compliance considerations reside within Nue Life. Of course, within the contractual arrangement, they are obliged to comply with that. In fact, they've been very, very good partners in terms of updating and modifying their process actually to comply with some recommendations that Paula mentioned as well as our medical teams mentioned in terms of best practices. From a regulatory perspective, there's not actually very much that's unique. In fact, in terms of a liability risk assessment, the bulk of the liability would otherwise reside with Nue Life as each person who goes through it is officially a Nue Life patient. In terms of capacity at our clinics, you know, this certainly expands our capacity. One of the things that we've become aware of is that our brand reach is quite substantial. We generate many, many website visitors per day, but in part because of the geographic limitations of where our clinics are located, we can't service many people. We do believe that this is going to extend the reach of people who we are able to treat through Fieldtrip. We don't anticipate that there will be too much diversion of people who opt in for the at home program versus the in-clinic program. It is too early to say, but by and large, we believe that it is really serving different audiences or that some people who come in from the in-clinic experience may, after completing the treatment protocol with us, may choose to do it at home, as a continuation of their care, just given the facility it provides. Again, we're just getting initial feedback now, so it is too early to provide too much guidance on that. All right. Thank you very much. I appreciate the additional clarity. I would like to change topics a bit and ask about PPD in particular. How frequently do mothers with PPD seek treatment as opposed to kind of, you know, waiting it out? Would you expect that program to require significant patient outreach and education, or is there a built-up desire in that market for better treatments given the significant unmet need? Good point. Yeah, we do believe that there's a pent-up need that we can address. I think that's evident in sometimes the speed at which patients have been recruited in prior studies. I'll say also that. My brain just stopped. I lost track of where I was headed on this. Sorry. All right. No problem. Michael, was there a follow-up on that? Yeah. Sorry. I just have one more question regarding clinical trial cost, specifically how much you're expecting the phase I to cost you, in particular, given that Australia is, you know, generally pretty affordable for clinical trials. I just remembered where I was headed on the other. I'm sorry about that. Just as a note, we're fully expecting a lot of that patient outreach to be started by our competitor who's already in the field and is actually doing a lot of that outreach and market building. I think we'll be able to benefit from that. Sorry about that. I just caught a pause in my brain. As for Australia, yes, we reached out to Australia because we could actually save some time relative to going to the U.S. There can be delays of three-six months, typically, in getting studies started in the U.S. in terms of getting the IND up and running. That's why we reached out to Australia. There's also the additional setting up a structure to recover R&D expenditures. We've done that to try to capture some of the costs back from the study we're currently running. All right. Thank you very much. Thank you. Thank you. As a reminder, if you would like to ask a question, please press star one on your telephone keypad. There are no further questions at this time. I would like to turn the call back over to Ronan Levy for any closing comments. Thank you, operator, and thank you to our investors for the support and to all the analysts for the calls, for the questions today. We're confident that the future of our drug development and clinics businesses will each be strengthened as separate entities. We're focused on continuing to foster innovation and developing innovative psychedelic-assisted therapies for those suffering mental health conditions while also setting the companies up for long-term success and increased shareholder value. With that, I'll ask the operator to close the lines. Thank you. This does conclude today's teleconference. We appreciate your participation. You may disconnect your lines at this time. Enjoy the rest of your day.